Nymox Pharmaceutical Corporation (NYMX) Shares Bought by Wedbush Securities Inc.
Wedbush Securities Inc. raised its position in Nymox Pharmaceutical Corporation (NASDAQ:NYMX) by 30.6% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 234,692 shares of the biopharmaceutical company’s stock after buying an additional 55,000 shares during the period. Wedbush Securities Inc.’s holdings in Nymox Pharmaceutical Corporation were worth $1,033,000 at the end of the most recent reporting period.
Separately, Rhumbline Advisers acquired a new position in shares of Nymox Pharmaceutical Corporation during the second quarter worth approximately $134,000. Hedge funds and other institutional investors own 1.78% of the company’s stock.
Nymox Pharmaceutical Corporation (NYMX) opened at 3.49 on Friday. The company has a 50 day moving average price of $3.92 and a 200-day moving average price of $3.81. The firm’s market capitalization is $182.76 million. Nymox Pharmaceutical Corporation has a 52 week low of $2.00 and a 52 week high of $5.79.
COPYRIGHT VIOLATION NOTICE: “Nymox Pharmaceutical Corporation (NYMX) Shares Bought by Wedbush Securities Inc.” was first posted by Daily Political and is owned by of Daily Political. If you are reading this story on another domain, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The original version of this story can be read at https://www.dailypolitical.com/2017/08/13/nymox-pharmaceutical-corporation-nymx-shares-bought-by-wedbush-securities-inc.html.
Separately, ValuEngine upgraded Nymox Pharmaceutical Corporation from a “sell” rating to a “hold” rating in a report on Friday.
In other news, Director James George Robinson purchased 15,000 shares of Nymox Pharmaceutical Corporation stock in a transaction that occurred on Wednesday, June 21st. The stock was acquired at an average cost of $3.77 per share, for a total transaction of $56,550.00. Following the purchase, the director now directly owns 3,008,150 shares of the company’s stock, valued at approximately $11,340,725.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders purchased a total of 152,500 shares of company stock valued at $583,370 over the last 90 days. 54.00% of the stock is currently owned by corporate insiders.
Nymox Pharmaceutical Corporation Company Profile
Nymox Pharmaceutical Corporation, formerly Corporation Pharmaceutique Nymox, is a biopharmaceutical company. The Company is focused on developing its drug candidate, NX-1207, for the treatment of benign prostatic hyperplasia (BPH) and the treatment of low-grade localized prostate cancer. The Company markets NicAlert and TobacAlert tests that use urine or saliva to detect use of tobacco products.
Want to see what other hedge funds are holding NYMX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Nymox Pharmaceutical Corporation (NASDAQ:NYMX).
Receive News & Ratings for Nymox Pharmaceutical Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nymox Pharmaceutical Corporation and related companies with MarketBeat.com's FREE daily email newsletter.